EXPLORE!

Samples Taken from Gambian Pharma Firm Meet the Required Standards: India to WHO

  544 Views

Reuters    16 December 2022

In a letter to the World Health Organization dated December 13, India clarified that samples taken from Maiden Pharma, whose products were linked to the deaths of children in the Gambia, meet all the required specifications. In October, the Indian health authorities announced that the production of the cough and cold syrups at the Maiden Pharmaceuticals factory in Sonepat was halted after the global health agency reported that the drug might be linked to the deaths of 69 children in Gambia.

 

India′s drugs controller general, V.G. Somani, stated that tests on samples of Maiden Pharma′s products were found to be complying with specifications and showed the samples were not contaminated with ethylene glycol and diethylene glycol.

 

On Thursday, the Union Health Ministry released a copy of the letter to reporters. Additionally, the letter pointed out that the WHO′s statement in October, linking the deaths to the cough syrup manufactured in India, caused "irreparable damage" to the country′s supply chain of pharmaceutical products.

 

(Source: https://health.economictimes.indiatimes.com/news/pharma/india-says-samples-taken-from-pharma-firm-linked-to-gambia-deaths-meet-required-standards/96265046?utm_source=Mailer&utm_medium=newsletter&utm_campaign=ethealth_news_2022-12-16&dt=2022-12-16 )

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.